These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26979520)

  • 1. The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers.
    El Messaoudi S; Russel FG; Colbers A; Bandell CC; van den Broek PH; Burger DM; Rongen GA; Riksen NP
    Eur J Clin Pharmacol; 2016 Jun; 72(6):725-30. PubMed ID: 26979520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
    Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
    Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
    Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
    Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
    Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
    Li J; Klemm K; O'Farrell AM; Guler HP; Cherrington JM; Schwartz S; Boyea T
    Curr Med Res Opin; 2010 Aug; 26(8):2003-10. PubMed ID: 20583949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
    Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
    Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects.
    Kim SY; Jeon JY; Park SJ; Kim MG
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):576-584. PubMed ID: 30329224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions between topiramate and pioglitazone and metformin.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald D
    Epilepsy Res; 2014 Nov; 108(9):1519-32. PubMed ID: 25219351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects.
    Rocha JF; Vaz-da-Silva M; Almeida L; Falcão A; Nunes T; Santos AT; Martins F; Fontes-Ribeiro C; Macedo T; Soares-da-Silva P
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):255-61. PubMed ID: 19356391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
    Macha S; Dieterich S; Mattheus M; Seman LJ; Broedl UC; Woerle HJ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):132-40. PubMed ID: 23253948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
    Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.
    Ding Y; Jia Y; Song Y; Lu C; Li Y; Chen M; Wang M; Wen A
    Eur J Clin Pharmacol; 2014 Feb; 70(2):141-6. PubMed ID: 24170325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets.
    Ghim JL; Phuong NTT; Kim MJ; Kim EJ; Song GS; Ahn S; Shin JG; Kim EY
    Drug Des Devel Ther; 2019; 13():1623-1632. PubMed ID: 31190741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.